1. Home
  2. ECPG vs GENB Comparison

ECPG vs GENB Comparison

Compare ECPG & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

N/A

Current Price

$108.92

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

Logo Generate Biomedicines Inc. Common Stock

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.05

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ECPG
GENB
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1999
2026

Fundamental Metrics

Financial Performance
Metric
ECPG
GENB
Price
$108.92
$12.05
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
★ $131.33
$26.25
AVG Volume (30 Days)
213.3K
★ 851.2K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 287.14
N/A
EPS
★ 12.21
N/A
Revenue
★ $1,768,802,000.00
N/A
Revenue This Year
$8.01
N/A
Revenue Next Year
$1.42
N/A
P/E Ratio
$8.98
★ N/A
Revenue Growth
★ 34.37
N/A
52 Week Low
$47.49
$11.00
52 Week High
$126.74
$22.67

Technical Indicators

Market Signals
Indicator
ECPG
GENB
Relative Strength Index (RSI) 53.97 41.38
Support Level $92.48 $11.93
Resistance Level $126.74 $14.29
Average True Range (ATR) 5.04 1.20
MACD 0.48 -0.08
Stochastic Oscillator 36.26 11.29

Price Performance

Historical Comparison
ECPG
GENB

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: